top of page

FDA grants Breakthrough Therapy designation to AstraZeneca's Lynparza in mCRPC

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for AstraZeneca’s Lynparza (olaparib) for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page